Evidence map›Paper›PMID 27997228›Full record

ArticleAmerican journal of public health2017

Comprehensive HIV Prevention for Transgender Persons.

Mary Spink Neumann, Teresa J Finlayson, Nicole L Pitts, JoAnne Keatley

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of public health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
8.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. HIV seroprevalence in five key populations in Europe: a systematic literature review, 2009 to 2019.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mary Spink NeumannMary Spink Neumann and Teresa J. Finlayson are with the Office of the Director, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Nicole L. Pitts is with ICF International, Atlanta. JoAnne Keatley is with the Department of Family and Community Medicine, University of California, San Francisco.
Teresa J FinlaysonMary Spink Neumann and Teresa J. Finlayson are with the Office of the Director, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Nicole L. Pitts is with ICF International, Atlanta. JoAnne Keatley is with the Department of Family and Community Medicine, University of California, San Francisco.
Nicole L PittsMary Spink Neumann and Teresa J. Finlayson are with the Office of the Director, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Nicole L. Pitts is with ICF International, Atlanta. JoAnne Keatley is with the Department of Family and Community Medicine, University of California, San Francisco.
JoAnne KeatleyMary Spink Neumann and Teresa J. Finlayson are with the Office of the Director, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Nicole L. Pitts is with ICF International, Atlanta. JoAnne Keatley is with the Department of Family and Community Medicine, University of California, San Francisco.
National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

Transgender persons are at high risk for HIV infection, but prevention efforts specifically targeting these people have been minimal. Part of the challenge of HIV prevention for transgender populations is that numerous individual, interpersonal, social, and structural factors contribute to their risk. By combining HIV prevention services with complementary medical, legal, and psychosocial services, transgender persons' HIV risk behaviors, risk determinants, and overall health can be affected simultaneously. For maximum health impact, comprehensive HIV prevention for transgender persons warrants efforts targeted to various impact levels-socioeconomic factors, decision-making contexts, long-lasting protections, clinical interventions, and counseling and education. We present current HIV prevention efforts that reach transgender persons and present others for future consideration.

Indexed as

Transgender PersonsFemaleHIV InfectionsHumansMaleRisk Factors

Identifiers

PMID27997228
PMCPMC5227924
OpenAlexW2563832611

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.